CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Decision Support System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02558491
NCT02558491N/ACompleted

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

Daniel Chernavvsky, MD·interventional·Posted Sep 24, 2015·Updated Aug 7, 2024

In Brief

A clinical study evaluating Decision Support System and Usual Care for Type 1 Diabetes Mellitus. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to demonstrate the safety and feasibility of a decision support system aimed at reducing glucose variability in T1DM patient using an insulin pump.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 24, 2015
Enrollment StartSep 1, 2015
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.8 years ago

Interventions

Decision Support Systemdevice

The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump or MDI. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements: 1. An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data 2. An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment. 3. A smart bolus calculator based on CGM glucose measurements and insulin sensitivity estimation.

Usual Careother

During the Control study admission, DiAs will be programmed with the home insulin dosing parameters. The study subject will use the home basal/bolus MDI or continuous subcutaneous insulin infusion (CSII) insulin regimen via the home insulin pens or pump and determine the amount of insulin to give for the entire admission per the subject's home carb counting parameters and as calculated by the DiAs meal screen.